These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7199703)

  • 1. [Value of prostaglandin E1 in the treatment of cyanotic congenital heart defects in infants].
    Dymnicka S; Bielińska B; Ereciński J; Machnowski W
    Pediatr Pol; 1981 Oct; 56(10):1243-8. PubMed ID: 7199703
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostaglandin treatment of newborns with ductal-dependent congenital heart disease.
    Linday LA; Engle MA
    Pediatr Ann; 1981 Apr; 10(4):29-38. PubMed ID: 7232040
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacologic use of prostaglandin E1 in infant with congenital heart disease.
    Heymann MA
    Am Heart J; 1981 Jun; 101(6):837-43. PubMed ID: 7234660
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.
    Heymann MA; Clyman RI
    Pharmacotherapy; 1982; 2(3):148-55. PubMed ID: 6763200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ductus arteriosus: why and how to manipulate its patency.
    Drummond WH; Bucciarelli RL; Gessner IH
    J Fla Med Assoc; 1983 Sep; 70(9):788-93. PubMed ID: 6355376
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacologic dilatation of the ductus arteriosus with prostaglandin E1 in infants with congenital heart disease.
    Graham TP; Atwood GF; Boucek RJ
    South Med J; 1978 Oct; 71(10):1238-41, 1246. PubMed ID: 81528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prostaglandin E-2 in cyanotic heart defects in newborn (author's transl)].
    Beitzke A
    Klin Padiatr; 1981 Sep; 193(5):385-9. PubMed ID: 7289432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E2 administration in infants with ductus-dependent cyanotic congenital heart disease.
    Thanopoulos BD; Andreou A; Frimas C
    Eur J Pediatr; 1987 May; 146(3):279-82. PubMed ID: 3474149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palliation of cyanotic congenital heart disease in infancy with E-type prostaglandins.
    Neutze JM; Starling MB; Elliott RB; Barratt-Boyes BG
    Circulation; 1977 Feb; 55(2):238-41. PubMed ID: 64317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Skeletal side effects of treatment with prostaglandin E1].
    Persigehl M; Hövels-Gürich H; von Bernuth G
    Rofo; 1984 Oct; 141(4):427-30. PubMed ID: 6436918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of clinical response to prostaglandin E1 in a cyanotic infant with congenital absence of the ductus arteriosus.
    Hamilton WT; Lacina SJ; Bharati S; Lev M; Arcilla RA
    Cathet Cardiovasc Diagn; 1982; 8(3):273-6. PubMed ID: 7201887
    [No Abstract]   [Full Text] [Related]  

  • 12. Transcutaneous PO2 monitoring in infants with cyanotic congenital heart disease treated with prostaglandin E1.
    Kimble KJ; Ariagno RL; Pitlick P
    Pediatr Cardiol; 1983; 4(2):87-9. PubMed ID: 6878077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandin E1 in neonates with critical congenital heart disease.
    Dungan WT; Norton JB; Readinger RI; Sotomora RF
    J Ark Med Soc; 1982 Oct; 79(5):167-70. PubMed ID: 6183249
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prostaglandin treatment of ductus-dependent congenital heart defects].
    Olsson B; Björkhem G; Lundström NR
    Lakartidningen; 1984 Oct; 81(40):3619-22. PubMed ID: 6541738
    [No Abstract]   [Full Text] [Related]  

  • 15. [Anesthesia for neonates and young infants with ductus dependent cardiac malformations treated with prostaglandin E1].
    Fujii S; Nagai I; Yonei A; Sari A; Baba K
    Masui; 1984 May; 33(5):545-9. PubMed ID: 6540818
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of prostaglandin E1 on the hemodynamics in newborn infants with pulmonary atresia (author's transl)].
    Mocellin R; Sauer U; Schumacher G; Kellner M; Schöber JG
    Z Kardiol; 1978 Aug; 67(8):572-7. PubMed ID: 695809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects.
    Park IS; Nihill MR; Titus JL
    J Am Coll Cardiol; 1983 Feb; 1(2 Pt 1):471-5. PubMed ID: 6681824
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical management of infants and children with congenital heart disease.
    Moodie DS
    Cardiovasc Clin; 1981; 12(2):177-86. PubMed ID: 7201345
    [No Abstract]   [Full Text] [Related]  

  • 19. Proceedings: Emergency treatment of certain cyanotic heart defects with prostaglandin E2.
    Olley PM; Coceani F
    Br Heart J; 1976 Aug; 38(8):877. PubMed ID: 973917
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of prostaglandin E1 for maintaining the patency of the ductus arteriosus.
    Noah ML
    Adv Prostaglandin Thromboxane Res; 1978; 4():355-62. PubMed ID: 347914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.